Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1721 to 1730 of 2605 total matches.
Imvexxy - Another Estradiol Vaginal Insert for Dyspareunia
The Medical Letter on Drugs and Therapeutics • Sep 10, 2018 (Issue 1555)
randomized to receive
Table 1. Some Drugs for Vulvovaginal Atrophy (VVA)
Drug Available Formulations Usual ...
The FDA has approved an estradiol softgel vaginal
insert (Imvexxy – TherapeuticsMD) for treatment of
postmenopausal women with moderate to severe
dyspareunia due to vulvovaginal atrophy (VVA).
Imvexxy is the second estradiol vaginal insert to be
approved in the US; Vagifem, an intravaginal tablet
formulation, was the first. Vagifem and Imvexxy are
both available in inserts containing 10 mcg of estradiol;
Imvexxy is also available in a 4-mcg strength.
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
through 18 months of treatment.9 The drug did not signifi
cantly reduce loss of visual acuity in either ...
The FDA has approved the complement C5 inhibitor
avacincaptad pegol (Izervay – Iveric) for intravitreal
treatment of geographic atrophy (GA) secondary
to age-related macular degeneration (AMD).
Avacincaptad pegol is the second complement
inhibitor to be approved in the US for this indication;
pegcetacoplan (Syfovre), a complement C3 and C3b
inhibitor, was approved earlier.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):15-6 doi:10.58347/tml.2024.1694d | Show Introduction Hide Introduction
In Brief: Does Acetaminophen Increase Blood Pressure?
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011 (Issue 1362)
The Medical Letter®
On Drugs and Therapeutics
Volume 53 (Issue 1362)
April 18, 2011 ...
A recent article in Circulation reported that acetaminophen (Tylenol, and others; paracetamol outside the US) increased blood pressure in patients with coronary artery disease. This conclusion was based on a randomized, placebo-controlled crossover trial in 33 patients; acetaminophen 1 g three times daily for 2 weeks was associated with statistically significant increases in blood pressure of 2.9 mmHg systolic and 2.2 mmHg diastolic.1NSAIDs can increase blood pressure; the mechanism is thought to be inhibition of cyclooxygenase leading to decreased renal prostaglandin activity. Acetaminophen...
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
cases in the week ending January 14,
2023, up from 7% of cases 4 weeks earlier.4
1. FDA. Drug safety ...
The FDA has warned that the investigational long-acting
monoclonal antibodies tixagevimab and
cilgavimab (Evusheld – AstraZeneca) are unlikely
to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2. Evusheld is available under an Emergency Use
Authorization (EUA) for IM pre-exposure prophylaxis of
COVID-19 in persons ≥12 years old who weigh ≥40 kg
and have either a history of a severe adverse reaction
that prevents their vaccination against COVID-19 or
moderate or severe immune compromise.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e25 doi:10.58347/tml.2023.1669e | Show Introduction Hide Introduction
In Brief: Hyperthermia with Scopolamine Patches
The Medical Letter on Drugs and Therapeutics • Jun 30, 2025 (Issue 5114)
drug,
is FDA-approved for prevention of nausea and
vomiting associated with motion sickness ...
The FDA has required a new warning in the label for
the scopolamine transdermal patch (Transderm-Scōp, and generics) about a risk of serious or fatal
hyperthermia. Scopolamine, an anticholinergic drug,
is FDA-approved for prevention of nausea and
vomiting associated with motion sickness or recovery
after surgery in adults; it is often used off-label to
reduce drooling in children and adolescents with
neurologic disorders.
Med Lett Drugs Ther. 2025 Jun 30;67(5114):1 doi:10.58347/tml.2025.5114a | Show Introduction Hide Introduction
Finasteride and Minoxidil for Alopecia Revisited
The Medical Letter on Drugs and Therapeutics • Nov 21, 2005 (Issue 1222)
Letter
®
On Drugs and Therapeutics
IN THIS ISSUE
Volume 47 (Issue 1222)
November 21, 2005 ...
Finasteride and minoxidil continue to be the only drugs approved by the FDA to treat alopecia. Since these agents have different mechanisms of action, some clinicians have used both to treat hair loss in men.
Adapalene-Benzoyl Peroxide (Epiduo) for Acne
The Medical Letter on Drugs and Therapeutics • Apr 20, 2009 (Issue 1310)
The Medical Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 ...
Epiduo gel (Galderma), a fixed-dose combination of adapalene 0.1% (Differin), a synthetic retinoid analog, and benzoyl peroxide (BPO) 2.5%, an oxidizing agent, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old.
Ustekinumab (Stelara) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 25, 2010 (Issue 1330)
The Medical Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 ...
The FDA has approved the use of ustekinumab (Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors.
Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
combination of
the amide local anesthetic bupivacaine and the nonsteroidal
anti-inflammatory drug (NSAID ...
The FDA has approved a fixed-dose combination
of the amide local anesthetic bupivacaine and
the nonsteroidal anti-inflammatory drug (NSAID)
meloxicam as an extended-release (ER) solution
(Zynrelef – Heron) for single-dose, intraoperative,
soft-tissue or periarticular instillation to provide
postsurgical analgesia for up to 72 hours in adults
undergoing foot and ankle, small-to-medium open
abdominal, or lower extremity total joint arthroplasty
surgical procedures.
Acetaminophen Safety - Deja Vu
The Medical Letter on Drugs and Therapeutics • Jul 13, 2009 (Issue 1316)
IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS
The Medical Letter
®
On Drugs and Therapeutics ...
Concerns have surfaced again at the FDA and in the media about the safety of acetaminophen and the multiplicity of products on the market in the US that contain various amounts of it.